Redhill Biopharma Says Opaganib Delivered A Statistically Significant Increase In Survival Time At 150 mg/kg Twice Daily Dose In The United States Army Medical Research Institute Of Infectious Diseases In Vivo Ebola Virus Study
Portfolio Pulse from Benzinga Newsdesk
Redhill Biopharma announced that its drug Opaganib showed a statistically significant increase in survival time at a 150 mg/kg twice daily dose in an Ebola Virus study conducted by the United States Army Medical Research Institute of Infectious Diseases.
October 03, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Redhill Biopharma's positive results from the Ebola Virus study could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given the significance of these results, it's likely that Redhill Biopharma's stock will see a positive impact in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100